What You Should Know:
- Certara, a global leader in model-informed drug development, today announced an expanded collaboration with Merck, known as MSD outside of the United States and Canada.
- The strategic agreement will see Merck increase its use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This builds upon Merck’s existing technology collaboration with Certara aimed at aiding regulatory
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Eliminating Cancer Treatment Side-Effects Through Targeted Drug Delivery
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer cases for the first time in history. This number is staggering and signifies that cancer is truly a disease that impacts many lives each day.
While not all of these cases result in the grueling treatment associated with chemotherapy and radiation, many of those diagnosed will face the difficult road to recovery. Patients in chemotherapy experience a range of symptoms, from
Read More
Lieber Institute and AWS Collaborate to Optimize Drug Discovery for Brain Disorders
What You Should Know:
- The Lieber Institute for Brain Development (LIBD) is expanding its technology capabilities on Amazon Web Services (AWS), migrating its IT infrastructure to fully utilize AWS generative AI and compute services to advance its research.
- A recipient of the 2024 AWS IMAGINE Grant, the Institute plans to develop a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as
Read More
Nicoya Lifesciences Acquires Applied Photophysics to Accelerate Drug Discovery
What You Should Know:
- Nicoya Lifesciences, Inc., a leading provider of advanced biologics characterization tools for drug discovery and development, today announced its acquisition of Applied Photophysics, a UK-based provider of biophysical characterization instrumentation.
- Applied Photophysics, bringing a 50-year history of delivering established analytical methods and reliable instrumentation, will now operate as part of Nicoya.
Nicoya Expands Biopharmaceutical Analytics
Read More
Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering
What You Should Know:
- Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers of side effects.
- The round was led by HCVC, with participation from Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors.
- The funds will be used to accelerate the development of kyron.bio’s proprietary
Read More
Cycle Time is the New Currency of Drug Development
For years, the life sciences industry has been trying to address the same R&D challenges: rising costs, patient recruitment and retention, and difficulty maximizing ROI. Drug development is expensive, and failure rates remain high. Studies estimate the total cost to develop a new drug is between $300 million and nearly $4.5 billion. Meanwhile, clinical trial cycle times continue to lengthen – significantly impacting overall drug development timelines. Clinical trials are increasingly
Read More
Salt AI Partners with Ellison Medical Institute to Advance AI in Cancer Research
What You Should Know:
- Salt AI, a company founded by the high-performance computing (HPC) team behind MySpace, is making significant strides in AI-driven drug discovery through its research partnership with the Ellison Medical Institute, led by cancer researcher Dr. David Agus.
- The partnership signifies Salt AI's formal entry into the life sciences sector and has already yielded notable advancements. Key among these is the ability to run AlphaFold2, a foundation model
Read More
Harnessing AI and LLMs to Accelerate Biomedical Discovery for Precision Medicine
The healthcare industry is experiencing a data and technological revolution that is accelerating drug discovery and delivery to patients. Over the past 15 years, we've seen an explosion of targeted therapies — including small molecules, immunotherapies, cell-based treatments, and more — all made possible by the integration of large-scale 'omics data with clinical insights, treatment approaches, and patient outcomes. However, despite these advancements, we still have a long way to go to fully
Read More
OSE Immunotherapeutics & Scienta Lab Partner to Advance AI-Driven Drug Discovery
What You Should Know:
- OSE Immunotherapeutics SA, a biotechnology company focused on developing innovative immunotherapies, and Scienta Lab, a pioneer in AI-driven precision immunology is forming a strategic collaboration to leverage the power of artificial intelligence (AI) in the fight against inflammatory diseases.
- The partnership will harness Scienta Lab's advanced AI platform, EVA, to identify predictive biomarkers of efficacy for immunotherapies. EVA is a multimodal
Read More
Is AI Failing Drug Development? The Unseen Challenges
For over a decade, we've heard about AI's transformative potential in therapeutics (Tx), but where's the evidence? Has it all been hype? Can AI still revolutionize Tx? Or is there something the AI experts aren't telling us?
First, some facts. The process of Tx development—from early clinical trials to FDA approval—is excruciatingly slow (over 10 years), expensive (over $2B, especially for immunotherapy drugs), and comes with a low probability of success (5% in Immune-Oncology, and similarly
Read More
